Get access

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Authors

  • Alexander M. Menzies,

    Corresponding author
    1. The University of Sydney, Sydney, NSW, Australia
    • Melanoma Institute Australia, Sydney, NSW, Australia
    Search for more papers by this author
  • Richard F. Kefford,

    1. Melanoma Institute Australia, Sydney, NSW, Australia
    2. The University of Sydney, Sydney, NSW, Australia
    3. Westmead Institute for Cancer Research, Sydney, NSW, Australia
    4. Westmead Hospital, Sydney, NSW, Australia
    Search for more papers by this author
  • Georgina V. Long

    1. Melanoma Institute Australia, Sydney, NSW, Australia
    2. The University of Sydney, Sydney, NSW, Australia
    3. Westmead Institute for Cancer Research, Sydney, NSW, Australia
    Search for more papers by this author

CORRESPONDENCE Alexander Menzies, e-mail: alexander.menzies@sydney.edu.au

Summary

Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.

Get access to the full text of this article

Ancillary